Nektar Therapeutics
NKTR
138 hedge funds and large institutions have $1.4B invested in Nektar Therapeutics in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 69 increasing their positions, 35 reducing their positions, and 16 closing their positions.
97% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 35
36% more call options, than puts
Call options by funds: $7.03M | Put options by funds: $5.15M
21% more capital invested
Capital invested by funds: $1.16B → $1.4B (+$240M)
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
1% more funds holding
Funds holding: 136 → 138 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$40.1M |
| 2 |
JP Morgan Chase
New York
|
+$36.2M |
| 3 |
O
OppenheimerFunds
New York
|
+$18.5M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$6.65M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.61M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.96M |
| 4 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$3.75M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.28M |
NKTR Hedge Fund Activity: Q1 2014 in Review
138 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2014, worth a combined $1.4B — up 21% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NKTR positions and 16 closed out — a net gain of 3 holders — while 69 added to existing stakes and 35 trimmed.
The largest buyer was Primecap Management, adding an estimated $40.1M. The largest seller was D.E. Shaw & Co, cutting an estimated $6.65M.
- 138 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2014, up from 136 in Q4 2013.
- Funds reported $1.4B of Nektar Therapeutics stock for Q1 2014, up 21% quarter-over-quarter.
- 19 funds opened new Nektar Therapeutics positions in Q1 2014 and 16 closed out, a net change of +3 holders.
- The largest Nektar Therapeutics buyer in Q1 2014 was Primecap Management, an estimated $40.1M added.
- The largest Nektar Therapeutics seller in Q1 2014 was D.E. Shaw & Co, an estimated $6.65M sold.
Based on aggregated 13F filings for Q1 2014.